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1ABSTRACT
Optic nerve disintegration as a visuospatial cognitive predictor of 
Parkinson’s disease
Jae Jung Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Phil Hyu Lee)
Objective: To explore the microstructural integrity of the optic nerve and 
its role as a visuospatial cognitive predictor in patients with de novo 
Parkinson’s disease (PD) using diffusion tensor image-based magnetic 
resonance scans.
Methods: We enrolled 82 patients with de novo PD; 36 patients had 
drug-induced parkinsonism (DIP), and 36 were normal controls. 
Fractional anisotropy (FA) and apparent diffusion coefficient (ADC) 
were measured on the mid-portion of the intraorbital optic nerve. A linear 
mixed-effects model was used to evaluate PD patients based on a 
2longitudinal change in cognitive subscore of a comprehensive 
neuropsychological test and optic nerve integrity.
Results: The mean FA value in PD was significantly lower (0.552 ± 
0.103, p < 0.001) than that in DIP (0.645 ± 0.099) or the normal controls 
(0.689 ± 0.089), whereas the mean ADC value was significantly higher in 
the PD group compared to the DIP or control group (p < 0.001). Optic 
nerve integrity was not significantly related to parkinsonian motor 
severity, striatal dopamine transporter activity, or olfactory performance 
in PD patents. In a longitudinal assessment of cognition in PD patients, 
the lower FA group had a more rapid decline in Rey complex figure test 
performance (-4.26; 95% CI, -8.31 to -0.40; p = 0.031) and Clock 
drawing tests (-1.35; 95% CI, -2.59 to -0.11; p = 0.034) than the higher 
FA group.
Conclusion: This study demonstrated that microstructural integrity in the 
optic nerve was distorted in PD patients, and that this nerve integrity 
might act as a cognitive predictor of visuospatial dysfunction.
----------------------------------------------------------------------------------------
Key words : Parkinson’s disease, optic nerve, diffusion tensor image, 
cognition
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I. INTRODUCTION
Parkinson’s disease (PD) is a multi-system disorder that involves the 
nigrostriatal system as well as cognitive, behavioral, mood control, autonomic 
control, and sensory processing systems. Of these, visual processing-associated 
symptoms are common in patients with PD1 and can range from primary visual 
dysfunction, such as decreased visual acuity,2 contrast sensitivity,1 color 
perception,2 and ocular motor dysfunction3 to higher-order dysfunctions 
including visual perception,4 visual memory,1 or even visual hallucinations.5
Along with PD pathology-related neurochemical, structural, or functional 
alterations in the visual association cortex,6, 7 accumulating evidence has 
suggested that the retina is an important contributor to visual dysfunction in PD. 
The principal dopaminergic actors in the retina are the A18 amacrine cells, 
which control dark adaptation, color vision, and spatial contrast sensitivity 
4through interactions between inner and outer plexiform layers.8, 9 Pathological 
and in vivo studies have determined that PD patients exhibit retinal 
dopaminergic cell loss10 and retinal nerve fiber layer (RNFL) thinning.11 With 
regard to cognition, higher-order dysfunctions in visual processing are known to 
be an indicator of dementia in PD,12 whereas the role of primary visual 
dysfunction in the cognitive prognosis is unknown. 
Diffusion tensor imaging (DTI) has been developed to estimate microstructural 
integrity in white matter by measuring diffusion tensor, a three-dimensional unit 
of diffusion. This measure is mainly represented by indices such as fractional 
anisotropy (FA) and mean diffusivity or apparent diffusion coefficient (ADC), 
which reflect the directionality and magnitude of diffusion of water molecules, 
respectively. This technology has been widely used to evaluate white matter 
connectivity in PD and overall white matter involvement in nervous system 
disorders.13 In the present study, we examined the microstructural integrity of 
the optic nerve in de novo PD patients using DTI-based imaging analysis. In 
addition, we analyzed the association between optic nerve integrity and 
nigrostriatal dopaminergic and cognitive status to determine whether optic 
nerve integrity acts as a clinically prognostic marker of PD.
5II. MATERIALS AND METHODS
Subjects and clinical assessment 
We retrospectively reviewed medical records from 82 consecutive PD patients that 
attended the Movement Disorders Clinic at Yonsei University Severance Hospital 
from January 2009 to June 2013. PD diagnosis was determined based on the clinical 
criteria of the United Kingdom’s PD Society Brain Bank,14 and all patients with PD 
were determined to have a drug-naïve de novo status. A total of 36 control subjects 
that did not exhibit any symptoms of neurologic deficits and did not have any other 
symptom profiles of abnormal movements or gait problems were recruited during the 
same period. The patients with drug-induced parkinsonism (DIP) were determined by 
the criteria in a previously published study,15 and 36 eligible patients were finally 
included. All subjects involved in the present study underwent conventional brain 
magnetic resonance imaging (MRI) including DTI, and a [18F] 
N-(3-fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) 
positron emission tomography (PET) scan were performed to all PD or DIP 
participants at their initial evaluation. Subjects that suffered from any 
neurodegenerative or known ophthalmologic disorders, which were identified by 
medical records, an ophthalmologist, or a self-report of miscellaneous ocular 
problems (such as visual blurring, ocular pain, visuospatial dysfunction, or visual
hallucinations), were excluded from this study. The Unified PD Rating Scale 
(UPDRS) part III (during the off status) and the Cross Cultural Smell Identification 
Test (CCSIT) were completed at initial diagnosis in all patients with PD. We received 
6approval from the Institutional Review Board at Yonsei University Severance 
Hospital, and written consent was obtained from all participants.
Cognitive assessment
To determine cognitive status in PD, a comprehensive neuropsychological test was 
performed by an experienced neuropsychologist in all 82 patients with PD. This 
assessment was performed at baseline evaluation using the Seoul Neuropsychological 
Screening Battery (SNSB)16, 17 and a Korean version of the Mini Mental State 
Examination (K-MMSE).18, 19 The SNSB is composed of various task subsets in five 
cognitive domains, and we selected representative tasks for each domain as follows: 
Attention (digit span forward and backward), Language function (Korean version of 
the Boston Naming Test), Visuospatial function (Rey Complex Figure Test (RCFT) 
copying, 10-point clock drawing,20 six-point drawing interlocking pentagon21), 
Memory (verbal memory, 20-minute delayed recall using the Seoul Verbal Learning 
Test; visual memory, 20-minute delayed recall using the RCFT), and Frontal 
executive function (semantic and phonemic fluency using the Controlled Oral Word 
Association Test; Stroop color reading test). Additionally, we performed a 
subanalysis of longitudinal changes in cognitive function according to optic nerve 
integrity in 45 of 82 PD patients that had available neuropsychological test follow-up 
data.
MRI acquisition
7All scans were performed with a 3T MR imaging (Achieva; Philips Medical Systems, 
Best, the Netherlands) using a 32-channel sensitivity-encoding head coil. DTI was 
performed using a single-shot spin-echo EPI. The axial images were obtained parallel 
to the anterior/posterior commissure line. The parameters for DTI were as follows: 
FOV = 220 mm, voxel size = 1.72 x 1.72 x 2 mm3, TE = ~70 ms, TR = ~8000 ms, FA 
= 90°, slice gap = 0 mm, NEX = 1, b-factor = 600 s/mm2, non-cardiac gating, and 70 
axial slices. We acquired diffusion-weighted images from 32 non-collinear, 
non-coplanar directions, with a baseline image without diffusion weighting. Total 
acquisition time was 5 min 45 s. Isotropic fractional anisotropy (FA), trace, and 
apparent diffusion coefficient (ADC) maps were immediately generated on the 
console by the chosen software (Packman Tools; Philips Medical Systems).
Diffusion tensor image analysis
To obtain cross-sectional area measurements of the optic nerves, we made coronal 
reformatted FA and ADC maps using Aquarius iNtuition software (TeraRecon, Foster 
City, CA, USA) (Figure e-1). Circular regions of interest (ROIs) with a mean 
diameter of 7.6 mm2 (range, 5.8 – 8.2 mm2) were manually drawn on the mid-portion 
of the intraorbital optic nerve on FA and ADC maps. All ROIs were placed strictly 
within the optic nerve boundary to avoid contamination from adjacent fat or 
cerebrospinal fluid. FA and ADC values were measured in each optic nerve of all 
patients. For each patient, the mean FA and ADC values were calculated by averaging 
the values measured in bilateral optic nerves. To confirm the estimate consensus, two 
8board-certified neurologists (J.J.L. and Y.J.L.) separately conducted measurements of 
FA and ADC values and were blinded to patient information. The internal consistency 
(Cronbach’s alpha) was demonstrated by inter-rater values of 0.804 for FA and 0.826 
for ADC and intra-rater values of 0.886 for FA and 0.878 for ADC.
18F-FP-CIT PET acquisition
A 18F-FP-CIT PET scan was performed using a GE Discovery STe (DSTE) PET-CT 
scanner (GE Healthcare Technologies, Milwaukee, WI), which obtained images with 
a three-dimensional resolution of 2.3 mm at full-width at half-maximum. A 5mCi 
(185 MBq) of 18F-FP-CIT was injected intravenously, and images were acquired in 
three-dimensional mode at 120 KVp and 380 mAs during a 20-minute session that 
occurred 90 minutes after contrast injection.
Quantitative analyses of the 18F-FP-CIT image data
The quantitative analyses of the 18F-FP-CIT PET images were carried out according 
to a previously published procedure.22 Image processing was performed using SPM8 
(Wellcome Department of Imaging Neuroscience, Institute of Neurology, UCL, 
London, UK) in MATLAB 2013a for Windows (MathWorks, Natick, MA). 
Quantitative analyses were based on volumes of interests (VOIs), which were defined 
based on a template in standard space. All reconstructed PET images were spatially 
normalized to the Montreal Neurology Institute template space using a standard 
918F-FP-CIT PET template, which was created using the 18F-FP-CIT PET and T1 MRI 
scans of 13 normal controls to remove inter-subject anatomical variability. Twelve 
VOIs of bilateral striatal subregions and one occipital VOI were drawn on a 
coregistered spatially-normalized single T1 MRI and 18F-FP-CIT PET template image 
on MRIcro version 1.37 (Chris Rorden, Columbia, SC), based on a previous study.22
These VOIs were adjusted through a minor translation in our in-house VOI editing 
software called ANTIQUE.23 Each unilateral striatum was divided into six subregions, 
consisting of two caudate nucleus subregions (anterior and posterior), the ventral 
striatum, and three putaminal subregions (anterior, posterior, and ventral). Then, using 
the DAT activity concentration in each VOI, we estimated the surrogate of
non-displaceable binding potential (BPnd), defined as [(mean standardized uptake 
value (SUV) of the striatal subregion VOI - mean SUV of the occipital VOI)/mean 
SUV of the occipital VOI].24 Finally, the mean BPnd values of each pairwise striatal 
subregion were used for analyses.
Statistical analysis
To assess the demographic characteristics of the patients, an analysis of variance 
followed by multiple comparisons was used to compare group differences of 
continuous variables. The normality of the continuous variables was evaluated using 
the Kolmogorov–Smirnov test. The χ2 test was used for categorical variables. The 
group differences in mean FA and mean ADC were analyzed using analysis of 
covariance with adjustment for age, gender, and disease duration. To determine the 
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associations of mean FA or mean ADC with DAT activities of striatal subregions, 
UPDRS III, CCSIT, and K-MMSE in PD, the partial correlation coefficients 
controlled for onset age, gender, and disease duration were calculated. A linear 
mixed-effects model was adopted to determine associations between either FA or 
ADC and changes in cognitive performance as assessed by repetitive comprehensive 
neuropsychological tests. In this analysis, the PD group was dichotomized into lower 
or higher groups by the median value of FA or ADC, respectively. These models 
included random effects for intercept and subject, which accounted for the repeated 
measures among subjects. The interactions between time and dichotomized subgroup 
of FA or ADC represented the effects of FA or ADC on the change in the score of 
SNSB subsets over time. The independent variables of onset age, gender, and disease 
duration were used as adjustments. A two-tailed level of p <0.05 was considered to be 
statistically significant, and all statistical analyses were performed using SPSS for 
Windows 20.0(SPSS, Inc., Chicago, IL).
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III. RESULTS
Demographics and comparisons of optic nerve integrity among groups
Baseline demographic characteristics among the groups are summarized in Table 1.
There were no significant differences in age, gender, K-MMSE score, or duration of 
education among the groups. The mean disease duration and UPDRS-III score were 
1.3 ± 1.0 (range, 0.1 – 4.3) years and 22.0 ± 11.4 (range, 11 – 51) in patients with PD 
and 1.1 ± 0.8 (range, 0.4 – 2.8) years and 19.2 ± 9.7 (range, 6 – 48) in patients with 
DIP, which did not differ significantly. The drugs associated with decreased integrity 
in patients with DIP were gastrointestinal prokinetics (21), antipsychotics (15), 
antidepressants (11), antiarrhythmic agents (6), and anti-epileptics (3). The FA value 
was significantly lower in patients with PD (0.552 ± 0.103; interquartile range (IQR), 
0.462 – 0.639; p < 0.001) compared with patients with DIP (0.645 ± 0.099; IQR, 
0.586 – 0.703) or controls (0.689 ± 0.089; IQR, 0.639 – 0.741; table 2). Additionally, 
PD patients had a significantly higher ADC score (1334.7 ± 261.7 mm2/s; IQR, 
1146.6 – 1514.7; p < 0.001) compared with patients with DIP (1050.5 ± 252.9; IQR, 
951.5 – 1079.6) or controls (1071.6 ± 203.9; IQR, 931.1 – 1185.7; table 2 and figure 
1). No significant differences were found between the control and DIP groups in FA 
value (0.689 ± 0.089 vs. 0.645 ± 0.099, p = 0.999) or ADC value (1071.6 ± 203.9 vs. 
1050.5 ± 252.9, p = 0.999).
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Table 1. Demographic characteristics among controls, drug-induced parkinsonism 
patient, and Parkinson’s disease patients. 
Control DIP PD
Characteristics (n=36) (n=36) (n=82) p
Age (years) 67.1 ± 7.7 68.4 ± 8.5 68.5 ± 8.1 NS
Gender (Male / Female) 20 / 16 15 / 21 42 / 40 NS
K-MMSE (30) 27.9 ± 1.5 26.7 ± 2.5 26.9 ± 2.9 NS
Education (years) 10.8 ± 5.7 9.3 ± 4.3 9.9 ± 4.9 NS
Age of onset (years) 67.2 ± 8.4 67.1 ± 8.1 NS
Disease duration (years) 1.1 ± 0.8 1.3 ± 1.0 NS
UPDRS III 19.2 ± 9.7 22.0 ± 11.4 NS
Data are expressed as mean ± SD or number. 
DIP, drug-induced parkinsonism; PD, Parkinson’s disease; K-MMSE, Korean-Mini 
Mental Status Examination; UPDRS, Unified Parkinson’s disease rating scale; NS, no 
significance.
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Table 2. Comparison of optic nerve integrity among control, drug-induced 
parkinsonism patients, and Parkinson’s disease patients.
Control DIP PD
Characteristics (n=36) (n=36) (n=82) P*
FA 0.689 ± 0.089 0.645 ± 0.099 0.552 ± 0.103 < 0.001
ADC (mm2/s) 1071.6 ± 203.9 1050.5 ± 252.9 1334.7 ± 261.7 < 0.001
*Analysis of covariance adjusting for age, gender, and disease duration.
Data are expressed as mean ± SD.
DIP, drug-induced parkinsonism; PD, Parkinson’s disease; FA, fractional anisotropy; 
ADC, apparent diffusion coefficient.
Figure 1. Boxplot of fractional anisotropy and apparent diffusion coefficient in 
controls, drug-induced parkinsonism patient, and Parkinson’s disease patients. (A) 
Fractional anisotropy, (B) Apparent diffusion coefficient.
(A) (B)
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Correlation analyses of optic nerve integrity in PD with motor, premotor, and 
cognitive status surrogates
The age of disease onset in patients with PD was negatively correlated with BPnd in 
the anterior putamen (r = - 0.136, p = 0.024) and caudate nucleus (r = - 0.315, p < 
0.001). As expected, the UPDRS-III was negatively correlated with BPnd in the 
anterior putamen (r = - 0.278, p = 0.012) and caudate nucleus (r = - 347, p = 0.006). 
After adjusting for onset age, gender, and disease duration, the correlation analysis of 
optic nerve integrity and parkinsonian motor severity indicated that the values of FA 
and ADC were not associated with UPDRS III score or BPnd in any striatal 
subregions (Table 3). Additionally, neither the FA nor ADC value was significantly 
correlated with CCSI or K-MMSE score.
15
Table 3. Relationships between optic nerve integrity and clinical markers of 
parkinsonian motor severity, olfaction, general cognition, and dopamine transporter 
activities in patients with Parkinson’s disease.
FA ADC
r* p r* p
UPDRS III -0.202 0.125 -0.164 0.218
CCSIT 0.119 0.300 0.007 0.950
K-MMSE -0.049 0.683 0.036 0.768
BPnd of 
striatal subregions
  Anterior caudate -0.126 0.273 0.090 0.437
  Posterior caudate -0.124 0.278 0.173 0.136
  Ventral striatum -0.072 0.530 0.035 0.767
  Anterior putamen -0.093 0.417 0.076 0.516
  Posterior putamen -0.007 0.953 0.085 0.468
  Ventral putamen -0.035 0.763 0.136 0.241
*Partial correlation adjusting for age of onset, gender, and disease duration.
FA, fractional anisotropy; ADC, afferent diffusion coefficient; UPDRS, Unified 
Parkinson’s disease rating scale; CCSIT, Cross Cultural Smell Identification Test; 
K-MMSE, Korean-Mini Mental Status Examination; BPnd, non-displaceable binding 
potential.
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Association between optic nerve integrity and cognitive performance  
Multivariate linear regression analysis showed that neither FA nor ADC value was 
significantly associated with any cognitive subsets (Table e-1 in supplementary data).
Forty-five patients with PD completed a follow-up neuropsychological test with a 
mean interval of 2.5 years. The mean FA and ADC values in this subpopulation of PD 
were 0.451 ± 0.042 (IQR, 0.422 – 0.475) and 1406.6 ± 212.1 mm2/s (IQR, 1258.5 –
1519.7), respectively, in the dichotomized lower FA group and 0.540 ± 0.107 (IQR, 
0.432 – 0.653) and 1559.9 ± 162.3 mm2/s (IQR, 1408.0 – 1721.1) in the dichotomized 
higher ADC group. Table 4 shows changes in cognitive subscores of each PD patient 
between baseline and follow-up neuropsychological tests, according to optic nerve 
integrity. The lower FA group was strongly associated with a greater decline in RCFT
drawing (ß = -4.26 (1.91), p = 0.031) and clock drawing test (CDT) (ß = -1.35 (0.61), 
p = 0.034) compared to the higher FA group. No significant differences in interval 
changes in the remaining cognitive subsets were found between the lower and higher 
FA groups. However, a distinct pattern of changes in RCFT and CDT performance is 
demonstrated in Figure 2. Compared to the higher FA group, the lower FA group 
showed a steeper estimated slope (ES) of RCFT performance decline (ES [SD], -4.86 
(1.47) vs. -0.59 (1.23); 95% CI, -8.31 to -0.40; p = 0.031) and CDT performance 
(-0.96 (0.47) vs. 0.43 (0.38); 95% CI, -2.59 to -0.11; p = 0.034; table 5).
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Table 4. Linear mixed-effects model of repetitive comprehensive neuropsychological 
tests in patients with Parkinson’s disease.
Lower FA group Higher ADC group
ß† (SE) p ß† (SE) p
Attention
   Digit span forward -0.18 (0.47) 0.704 -0.54 (0.46) 0.254
   Digit span backward -0.06 (0.25) 0.810 -0.03 (0.25) 0.903
Language
   K-BNT -1.41 (2.57) 0.585 -0.65 (2.59) 0.802
Visuospatial function
   RCFT -4.26 (1.91) 0.031 -0.74 (2.02) 0.717
   CDT -1.35 (0.61) 0.034 -0.77 (0.63) 0.235
   Interlocking Pentagon -0.28 (0.53) 0.608 -0.04 (0.46) 0.930
Verbal memory (SVLT)
   Delayed recall -2.01 (2.30) 0.387 -2.59 (2.29) 0.266
Visual memory (RCFT)
   Delayed recall 1.87 (1.82) 0.309 -1.53 (1.83) 0.407
Frontal executive function
   COWAT, animal -2.39 (1.35) 0.082 -0.48 (1.40) 0.731
   COWAT, supermarket 0.04 (2.16) 0.985 1.79 (2.14) 0.408
   COWAT, phonemic -1.22 (3.26) 0.711 2.35 (3.26) 0.474
   Stroop color test -4.42 (8.55) 0.608 -6.55 (8.25) 0.152
Data are adjusted for age of onset, gender, and disease duration.
†Regression coefficients represent the difference in rate of change in each cognition 
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task between dichotomized groups. 
FA, fractional anisotropy; ADC, afferent diffusion coefficient; K-BNT, Korean 
version of the Boston naming test; RCFT, Rey complex figure test; CDT, clock 
drawing test; SVLT, Seoul verbal learning test; COWAT, Controlled oral word 
association test
19
Figure 2. Alterations in longitudinal visual cognitive function depending on 
level of fractional anisotropy in 45 patients with PD. (A) Rey complex figure 
test, (B) Clock drawing test.
Table 5. Rate of visual cognitive decline in respective lower FA and higher ADC 
group in Parkinson’s disease. 
Estimated slope*
95% CI p
Lower FA group Higher FA group
RCFT -4.86 (1.47) -0.59 (1.23) -8.31 to -0.40 0.031
CDT -0.96 (0.47) 0.43 (0.38) -2.59 to -0.11 0.034
* Adjustment for onset age, gender, and disease duration.
FA, fractional anisotropy; RCFT, Rey-Osterrieth complex figure test; CDT, 
clock drawing test.
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Supplementary data
Table e-1. The relationships between optic nerve integrity and baseline 
cognitive subscores in patients with Parkinson’s disease.
FA ADC
ß (SE) P* ß (SE) P*
RCFT -0.012 (0.008) 0.120 0.001 (0.003) 0.811
CDT -0.001 (0.002) 0.824 0.001 (0.001) 0.537
Interlocking pentagon -0.003 (0.002) 0.143 0.001 (0.001) 0.414
Digit span test, forward -0.003 (0.002) 0.121 0.001 (0.001) 0.893
Digit span test, backward -0.001 (0.002) 0.645 0.001 (0.001) 0.471
K-BNT -0.019 (0.011) 0.077 0.003 (0.004) 0.535
SVLT delayed recall -0.002 (0.003) 0.393 -0.001 (0.001) 0.369
RCFT delayed recall 0.002 (0.007) 0.768 0.001 (0.003) 0.649
COWAT, animal -0.011 (0.005) 0.063 0.001 (0.002) 0.803
COWAT, supermarket -0.008 (0.006) 0.205 0.001 (0.002) 0.884
COWAT phonemic -0.008 (0.012) 0.482 -0.009 (0.004) 0.054
Stroop test color reading -0.001 (0.003) 0.975 -0.011 (0.013) 0.423
*Multiple linear regression analysis adjusting for age at onset, gender, and 
disease duration.
FA, fractional anisotropy; ADC, afferent diffusion coefficient; K-BNT, Korean 
version of the Boston naming test; RCFT, Rey complex figure test; CDT, clock 
drawing test; SVLT, Seoul verbal learning test; COWAT, Controlled oral word 
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association test
Figure e-1. Diffusion tensor imaging of fractional anisotropy and apparent 
diffusion coefficient measurements in PD patients’ optic nerves. The horizontal 
sections of the images were converted and reformatted to the coronal plane 
using Aquarius iNtuition software (TeraRecon, Foster City, CA, USA) to draw 
the circular region of interest on the mid-portion of the intraorbital optic nerve. 
This was performed because the horizontal section of the diffusion tensor image 
was identified in our routine magnetic resonance process. The sectioning 
produced: a 1) mean value of fractional anisotropy or apparent diffusion 
coefficient, 2) diameter and area of the region of interest, which are indicated by 
a white arrow and red dotted boxes, respectively, in the bottom left corner. Top 
left, horizontal section; top right, 3D reconstructed image of maximum intensity 
projection; bottom left, coronal section; bottom right, sagittal section. A, 
anterior; P, posterior; L, left; R, right; H, head; F, foot.
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IV. DISCUSSION
Based on comparative analyses of optic nerve integrity using DTI scanning, the 
present study demonstrated that microstructural integrity in the optic nerve was 
distorted in patients with PD compared to normal controls. Optic nerve 
disintegration was not significantly correlated with baseline parkinsonian 
severity, nigrostriatal dopaminergic depletion, olfactory performance, or 
cognitive performance. However, PD patients in the lower FA group showed 
more profound longitudinal decline in visuospatial cognitive performance 
relative to those in the higher FA group, which might suggest that optic nerve 
integrity is an important factor in predicting visuospatial cognitive decline in 
PD. 
Because neurons in the retina project axons toward the optic nerve head and 
then eventually form an optic nerve bundle, optic nerve integrity might be 
influenced by pathological alterations in the retina. For example, retina 
thickness in patients with optic neuritis was well-correlated with optic nerve 
atrophy, which was quantified by MRI scans.25 In addition, ganglion cell layer 
thickness was a significant predictor of axonal damage around the optic disc in 
patients with PD.26 DTI can be used as a parameter and has been recognized as 
a valuable marker for determining axonal or myelin injury in the optic nerve.27
Therefore, a DTI analysis method has been widely used to assess several 
ophthalmological diseases, such as glaucoma,28 optic neuritis,29 and multiple 
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sclerosis,30 and microstructural changes in the optic nerve showed a close 
relationship with structural retinal changes.28 Accordingly, DTI analysis is 
adequate for assessing the integrity of the optic nerve due to the basic nature of 
the optic nerve with axonal organization and architecture. 
Along with a pathological report that dopaminergic neurons in the retina were 
decreased in PD patients, in vivo evidence has demonstrated that retina or 
macular thickness, determined by optical coherence tomography, was reduced 
in patients with PD. This structural change in the retina appears to be inversely 
correlated with disease duration or parkinsonian motor severity.26, 31
Additionally, several studies have indicated that patients with PD showed lower 
amplitudes and delayed latencies on visual evoked potential32, 33 and reduced 
amplitude on multifocal electroretinogram,33 suggesting functional alteration in 
the retina. In the present study, microstructural white matter integrity assessed 
by DTI was significantly altered in patients with PD compared with controls or 
DIP patients, which provides further in vivo evidence of optic nerve 
disintegration in PD. Even though the precise mechanism of optic nerve 
disintegration in PD has not yet been determined, the data from this study 
suggest that white matter disintegration is not ascribed to functional dopamine 
deficiency but to PD-related pathological changes.  
Interestingly, we found that optic nerve disintegration in patients with PD is a 
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remarkable factor for predicting the decreased visuospatial cognitive 
performance. In PD patients, visuospatial function deteriorated as the disease 
progressed,34 and visuospatial memory impairment was greater in severely 
disabled PD patients.35 Visual dysfunction is a strong predictor of dementia in 
PD.36 Accordingly, overall visual dysfunction is critical for PD patients and can 
influence everyday functioning, including activities of daily living,1 gait,37 and 
problems in driving,38 which lead to a lower quality of life and social isolation. 
However, there were no correlations between optic nerve disintegration and 
baseline MMSE scores or specific cognitive domains on comprehensive 
neuropsychological tests. As the subjects included in this study were in the early 
stage of PD without dementia, it was inferred that optic nerve disintegration has 
little influence on cognitive status in the early stages of PD. Rather, our data 
suggest that optic nerve integrity plays a putative role in cognitive decline when 
optic nerve disintegration is combined with extensive PD pathologies that 
involve visual cortical areas as the disease progresses. 
The correlation analysis indicated that optic nerve integrity in patients with PD 
was not significantly related to parkinsonian motor severity, striatal DAT 
activity, or olfactory performance. However, this data indicated that the optic 
nerve disintegration process might be independent of nigrostriatal dopaminergic 
degeneration in PD. According to pathological staging, the retina and optic 
nerve are positioned at a similar longitudinal level with the olfactory bulb in the 
anatomic structure of a bottom-up alpha synuclein deposition.39 Thus, 
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pathological changes in the retina and optic nerve might precede alpha 
synuclein deposition in the substantia nigra, suggesting a non-tangible 
relationship between optic nerve integrity and nigrostriatal system-dependent 
motor system in PD.
Optic nerve integrity in this study was not closely related to olfactory 
performance. A previous study indicated a close association between olfactory 
performance and cardiac sympathetic denervation;40 however, we suggest that 
the non-motor systems, as the main induction sites of alpha-synuclein 
accumulation, are closely involved in the development and progression of PD 
regardless of involvement of the nigral dopaminergic system. If this is true, the 
visual system might not serve as the main induction site of synuclein 
accumulation compared with olfactory and cardiac sympathetic systems. 
There were several strengths and limitations to this study. To the best of our 
knowledge, this is the first study to investigate and identify optic nerve 
disintegration in PD. A large number of drug-naïve de novo patients with PD 
and 18F-FP-CIT PET-supported diagnoses of the disease strengthened this study. 
However, atypical parkinsonian disorders could not be completely excluded due 
to the recruitment of early-stage patients and relatively short follow-up periods. 
Second, we could not evaluate structural or functional changes in the retina, 
which would provide clues about the relationship between the integrity of the 
retina and the optic nerve in PD. Finally, the present study did not examine 
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optic nerve integrity in other parkinsonism plus syndromes, which might have 
extended clinical applications. Therefore, a large-scale multicenter trial could be 
instrumental for confirming optic nerve integrity as a valuable biomarker in PD. 
In summary, our data suggest that optic nerve integrity is a useful marker for 
distinguishing PD from normal controls, and a parameter of DTI of the optic 
nerve could be used as a valuable predictor of declining visuospatial function in 
PD.
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V. CONCLUSION
In summary, our data suggest that being a useful marker for distinguishing PD 
from normal controls, a parameter of DTI on optic nerve might be regarded as a 
valuable predictor for decline of visuospatial function in PD.
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ABSTRACT(IN KOREAN)
파킨슨병 환자에서 시공간 인지 기능에 대한 시신경 손상의
예측성
<지도교수 이필휴>
연세대학교 대학원 의학과
이재정
목적: 새로이 진단된 파킨슨병 환자에서 시신경의 구조적 손상이
존재하는지 확인하기 위해 확산텐서 자기공명영상을 이용한 연구를
계획하였다. 
배경: 파킨슨병에서 시각 경로 전반에 걸친 시각 기능 장애에
대해서는 다양한 근거들이 제시되어 왔다. 특히 동물을 대상으로
하거나 파킨슨 환자를 대상으로 한 인체 연구 등 몇몇 연구들에서
망막에 존재하는 도파민 신경 세포의 변성이나  망막신경섬유층이
얇아져 있음을 밝혀 내었다. 시신경은 망막신경섬유층으로부터
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유래하는 축삭 다발로서 아직까지 파킨슨병에서는 연구가 이루어진
바가 없었다. 
방법: 파킨슨병 환자 82명 (남성 42명, 여성 40명), 약물 유발
파킨슨증 환자 36명, 정상군 36명으로부터 얻어진 확산텐서
자기공명영상을 이용하였다. 모든 파킨슨병 환자와 약물 유발
파킨슨증 환자에게 [18F] N-(3-Fluoropropyl)-2β-carbon 
ethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) 
양전자방출단층촬영 검사를 각각 시행하였다. 시신경의 구조적
안정성을 확인하기 위해 확산텐서 분석을 통해 얻어진
분획비등방성(fractional anisotropy) 지도와 겉보기확산계수
(apparent diffusion coefficient) 지도 각각에서 양측 눈확 내에
위치한 시신경의 가운데 부위에서 원 모양의 관심영역(region of 
interest)을 그렸고 이로부터 얻어진 측정치들을 평균낸 값을
이용하였다. 추가적으로 파킨슨병 환자의 임상 양상을 대변할 수
있는 척도들을 다음과 같이 확인하였다. 환자의 운동 증상을
측정하기 위해 통합된 파킨슨병 척도 파트 III, 운동증상 전 시기를
대변하는 Cross cultural smell identification test (CCSIT), 인지
상태를 확인하기 위해 통합적 신경심리 검사를 각각 시행하였다. 
결과: 분획``비등방성 측정치는 약물 유발 파킨슨증 환자 (0.645 ± 
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0.099) 나 정상군 (0.689 ± 0.089) 에 비해서 파킨슨병 환자 군
(0.552 ± 0.103, p < 0.001) 에서 의미 있게 낮았으며, 겉보기확산계수
측정치는 약물 유발 파킨슨증 환자 (1050.5 ± 252.9 mm2/s) 나
정상군 (1071.6 ± 203.9 mm2/s) 에 비해서 파킨슨병 환자 군
(1334.7 ± 261.7 mm2/s, p < 0.001) 에서 의미 있게 높게 확인되었다. 
파킨슨병 환자에서 분획비등방성 또는 겉보기확산계수 측정치와
18F-FP-CIT 양전자방출단층촬영에서 측정된 도파민운반활동
(dopamine transporter) 측정치, 통합된 파킨슨병 척도 파트 III, 
CCSIT 사이에 의미 있는 상관관계는 관찰되지 않았다. 신경심리
검사를 2회 이상 시행한 (평균 간격 2.5년) 파킨슨병 환자에서
분획비등방성이 낮은 군에서 높은 군에 비해 Rey-Osterrieth 
complex 그림 그리기 검사 (-4.26 ± 1.91; 95% CI, -8.31 to -0.40; p
= 0.031) 와 시계 그리기 검사 (-1.35 ± 0.61; 95% CI, -2.59 to 
-0.11; p = 0.034) 에서 더 빠른 악화가 관찰되었다. 
결론: 본 연구는 파킨슨병 환자의 시신경에서 미세한 구조적 손상이
존재함을 밝혀 내었으며, 이러한 손상은 파킨슨병 환자의 시각 인지
기능에 중요한 역할을 할 수 있음을 시사한다. 
---------------------------------------------------
핵심되는 말 : 파킨슨병, 시신경, 확산텐서영상, 인지
